GLP-1 Insurance in 2026: Formulary Wars, Medicare Doors, and How to Win the Exception

The most important GLP-1 number in your life is not a trial result — it's a formulary tier decided in a pharmacy-benefit-manager conference room you'll never see. In 2025–2026, those rooms rewrote who pays what: the largest PBM picked a winner between the two blockbuster molecules, Medicare's rules bent around new indications, and reported government pricing deals redrew the cash floor. This is the map of that terrain and, more usefully, the step-by-step method for locating yourself on it.

The employer landscape: coverage is a coin flip with paperwork

Roughly half of large employers now cover GLP-1s for weight — a share that grew for years and then wobbled as costs exploded, with some plans adding coverage while others retreated behind new requirements. Where coverage exists, it almost never exists plainly: prior authorization is near-universal, typically demanding a qualifying BMI (usually 30, or 27 with a comorbidity like hypertension or sleep apnea), documented lifestyle-program participation, and sometimes step therapy through older, cheaper agents first. Reauthorization then recurs, often annually, frequently conditioned on demonstrated weight loss — meaning the drug that's working must be proven to be working, on schedule, in paperwork. None of this is a reason to give up; it's a reason to treat coverage as a process you run rather than a fact you check once.

July 2025: the formulary shot heard round the market

Effective July 1, 2025, CVS Caremark — the country's largest pharmacy benefit manager — made Wegovy its preferred GLP-1 for weight management on its main commercial template and dropped Zepbound, steering millions of covered lives toward semaglutide regardless of the head-to-head trial in which tirzepatide had just won on weight loss (20.2% versus 13.7% in SURMOUNT-5). The decision was economics, not evidence: preferred placement follows negotiated rebates. For patients it created the signature absurdity of American drug pricing — people thriving on one molecule switched to the other by letter, while their physicians filed exceptions. Two durable lessons: your "choice" of molecule is often your PBM's choice unless you fight the exception process, and formulary preference is a moving target worth rechecking every plan year, because the next negotiation can flip it back.

Medicare: the exclusion and the three doors through it

Medicare Part D is barred by statute from covering drugs for weight loss — a 2003-era rule written before obesity pharmacotherapy worked. But the exclusion is indication-shaped, not molecule-shaped, and outcomes trials punched three doors through it. Semaglutide's cardiovascular indication (after SELECT's 20% event reduction) made Wegovy coverable for beneficiaries with established heart disease starting in 2024. Tirzepatide's sleep-apnea indication (December 2024) made Zepbound coverable for moderate-to-severe OSA with obesity. And diabetes has always been a door: Ozempic and Mounjaro remain coverable for their original indication. Meanwhile the direct-repeal story kept moving: a 2024 federal proposal to cover anti-obesity medication outright was not finalized in 2025, but late-2025 reporting described government agreements with both manufacturers pairing lower direct-purchase prices with a Medicare coverage pilot slated to phase in from 2026 — details that shifted repeatedly between announcement and implementation, so verify current CMS status rather than trusting any summary, ours included. The practical takeaway for beneficiaries hasn't changed: coverage flows through diagnoses, so a sleep study or cardiac history on file can be worth thousands of dollars a year.

The exception fight: what actually wins

When coverage is denied or the wrong molecule is preferred, the formulary-exception and appeal process is the tool, and it's more winnable than its paperwork suggests. The letter of medical necessity that succeeds contains specifics: the diagnosis codes (obesity plus every comorbidity — hypertension, prediabetes, OSA, osteoarthritis), the objective baseline (BMI, labs), prior treatment failures including any required step-therapy agents, the clinical rationale for this molecule (tolerability history, comorbidity fit — cardiovascular disease argues semaglutide, larger loss targets or OSA argue tirzepatide), and, on reauthorization, the response data showing the therapy is working. Denials come with appeal rights and deadlines printed on them; first-level appeals overturn a meaningful share of denials, and external review exists beyond that. Clinician offices file these daily — ask directly what documentation they need from you, and supply it the same week.

The cash lane as leverage, not just fallback

Even the insured should price the cash lane annually, because it disciplines everything else. Manufacturer-direct programs (LillyDirect vials, NovoCare) repeatedly cut prices through 2025 into 2026, with reported late-2025 agreements pushing entry pricing lower still — verify the current figure the week you decide. Verified compounded telehealth sits beneath that: our ledger's dated floor is $139/month tirzepatide and $119/month semaglutide on 12-month terms (one provider verified, ten pending — and see the disclosure on that provider). Savings cards can drop covered brand prescriptions to as little as $25/month depending on plan design. Knowing all three numbers turns an insurance denial from a wall into a comparison — sometimes the honest math says the appeal is worth weeks of fighting; sometimes it says the cash program costs less than the fight.

Your formulary, decoded in fifteen minutes

The method, start to finish. Log into your plan portal and open the formulary document (searchable PDF or lookup tool); search each drug by brand name — Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus. Record three things per drug: covered or excluded, the tier (which sets your copay class), and the letters beside it — PA (prior authorization), ST (step therapy), QL (quantity limit). Then open the PA criteria document — plans publish these — and read the actual requirements against your chart: qualifying BMI, comorbidity list, program-participation language, reauthorization terms. Finally, call the number on your card and ask the two questions the documents dodge: "what is my expected copay at tier X for this drug," and "is a formulary exception available if my physician documents medical necessity for the non-preferred agent?" Write down the date and the representative's name. You now know more about your real price than most prescribers will assume — bring it to the appointment.

Questions people actually ask

My employer excludes weight-loss drugs entirely. Dead end? Not quite: indication-based routes still apply (diabetes, cardiovascular, OSA where diagnosed), HR benefits teams do add coverage when employees ask in numbers, and the cash lane keeps falling. Exclusion is a detour sign, not a wall.

Do compounded programs ever bill insurance? Essentially no — compounded GLP-1s are a cash market. Insurance energy belongs on the FDA-approved products; cash comparison belongs on the ledger.

Is it worth switching plans during open enrollment over this? For a therapy costing four figures a year out of pocket, formulary coverage can outweigh premium differences — check the formularies of every plan you're offered before November, not after January.

My PA demands "6 months of documented lifestyle intervention." Now what? Start the documentation clock immediately — a dietitian referral, a logged program, clinician visit notes — and ask whether prior efforts in your chart already qualify. Plans accept history more often than patients assume; undocumented effort, however real, counts as zero.

A worked example: two patients, one drug, four prices

Numbers make the system legible. Consider tirzepatide for a 48-year-old with a BMI of 34 and treated hypertension. Scenario one, covered commercial plan, PA approved: tier-3 copay lands around $60–100/month, savings card potentially lower — call it roughly $1,000/year. Scenario two, same plan, PA denied and appeal pending: manufacturer-direct vials at the current cash program price, roughly $4,200–6,000/year at 2025-era tiers (verify — this program's prices moved repeatedly). Scenario three, no coverage, verified compounded program at the ledger floor: $139/month on a 12-month plan, $1,668/year, with the compounded caveats our legal guide details. Scenario four, Medicare beneficiary with documented moderate-to-severe OSA: Zepbound coverable under the sleep-apnea indication, cost defined by the plan's tier and the beneficiary's phase of the Part D benefit. Four rational patients, one molecule, a fourfold-plus price spread determined almost entirely by paperwork position — which is the entire argument for spending the fifteen minutes on your formulary before spending a dollar anywhere.

The reauthorization trap, and how to never fall in it

Approval is round one; keeping approval is the round patients lose by surprise. Most plans reauthorize GLP-1 coverage every six to twelve months against written criteria — commonly documented loss of at least 5% of baseline weight, continued program participation, and an active prescriber attestation — and a missed renewal doesn't send a warning, it sends a pharmacy rejection the week you're due for a refill. Run it like a deadline system: calendar the reauthorization date the day the initial approval arrives, book the supporting clinician visit a month ahead, and keep a one-page response file (start weight, current weight, waist, resolved or improved comorbidities, program logs) updated quarterly so the paperwork writes itself. If your loss has plateaued near the criteria threshold, read our plateau guide before the renewal visit — the broader dashboard of improvements it teaches you to document is precisely what turns a borderline reauthorization into an approved one.

References

Primary sources for this article (verify against PubMed / FDA before external citation): CVS Caremark formulary announcements (effective July 1, 2025); Lincoff et al., SELECT NEJM 2023 and FDA Wegovy CV indication (March 2024); FDA Zepbound OSA approval (December 2024); CMS Part D guidance on indication-based coverage; KFF employer health benefits surveys (2024–2025); late-2025 manufacturer–government pricing/Medicare pilot reporting (verify current status).